CompoAtlas

Transdermal Nicotine Patch 7mg/Day

Natural health product licensed in Canada

Licence holder
Dr. Reddy's Laboratories Canada Inc.
NPN or DIN-HM
02241227
Status
Active licence
Licence date
29 November 2007
Revision date
7 May 2025
Form
Timbre transdermique
Route of administration
Transdermique
Application type
DIN de transition

Oral dose analysis does not apply without an established exclusively oral route.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the source
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine

Source : Nicotine

Potency : 7 mg nicotine

17.5 mg

Non-medicinal ingredients

Acrylate vinylacetate copolymères, Capric triglycéride, methacrylic acid esters (copolymers), Paper, Aluminum

PopulationAgeQuantity per servingFrequency
AdultesNot specified1 patchNot specified

Uses authorised in Canada

Transdermal nicotine patch is indicated as a temporary aid used to facilitate smoking cessation in smokers who strongly desire to give up their smoking habit.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

Source

Official Health Canada record, licence 02241227

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).

Has the product changed? Photograph the packaging.

Enter to analyse, Shift+Enter for a new line